Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

An update from Nevada Sunrise Gold ( ($TSE:NEV) ) is now available. Nevada Sunrise Metals Corporation has clarified details of its investor relatio...

Nevada Sunrise Clarifies Investor Relations Agreement with Nicholas Winton

Morgan Stanley analyst Thibault Boutherin upgraded Novartis AG to a Buy today and set a price target of CHF115.00. Boutherin covers the Healthcare ...

Morgan Stanley upgrades Novartis AG (NOVN) to a Buy

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European investors thanks to, a...

Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?

Nevada Sunrise Gold ( ($TSE:NEV) ) has provided an announcement. Nevada Sunrise Metals Corporation has initiated an advertising and investor awaren...

Nevada Sunrise Launches Investor Awareness Campaign

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on November 21 and set a price target of CHF106.00. The company’s shares ...

Kepler Capital  Keeps Their Buy Rating on Novartis AG (NOVN)

Cineverse ( ($CNVS) ) has issued an announcement. On November 20, 2025, Cineverse Corp. amended its 2017 Equity Incentive Plan to increase the numb...

Cineverse Amends Equity Plan and Elects Board Members

Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Novartis AG yesterday. The company’s shares closed today at CHF100.42. Bouther...

Morgan Stanley Reaffirms Their Buy Rating on Novartis AG (NOVN)

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG yesterday and set a price target of CHF108.00. Cespedes covers the Health...

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Alliance Global Partners analyst Brian Kinstlinger maintained a Buy rating on Cineverse on November 18 and set a price target of $6.00. The company...

Alliance Global Partners Keeps Their Buy Rating on Cineverse (CNVS)

Olema Pharmaceuticals stock rallied on Tuesday alongside an update from rival drugmaker Roche.


Why Is Olema Pharmaceuticals Stock (OLMA) Up Today?

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG today and set a price target of CHF92.00. According to TipRanks, Hector...

Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The ...

Novartis AG (NOVN) Receives a Buy from Kepler Capital

Cineverse Corp. (($CNVS)) has held its Q2 earnings call. Read on for the main highlights of the call. Cineverse Corp.’s recent earnings call painte...

Cineverse Corp. Earnings Call: Growth Amid Challenges

In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Annovis Bio, with a price target of $17.00. According...

Canaccord Genuity Reaffirms Their Buy Rating on Annovis Bio (ANVS)

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$132.57	+0.16%	1.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$132.57	+0.2%	1.17M
3
4
5
6

NVS

NVS

No Data Available

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel